(Reuters)—On April 16, the U.S. Food & Drug Administration (FDA) cautioned that with a lot of its staff allocated to the coronavirus crisis, it may not be able to sustain its current level of timely reviews and approvals of marketing applications.
FDA says it was working to ensure that the drug programs continue to see minimal interruptions during this time. But if there was an increase in drugs shortages and supply disruptions, it will be ready to reprioritize its work.¹
The agency says its staff was working at full capacity to ensure that safe and effective drugs and biologics are available to the public, and are continuing to meet review goals, approve applications and communicate with drug developers.
Reporting By Mrinalika Roy in Bengaluru; Editing by Shinjini Ganguli
- U.S. Food and Drug Administration. Coronavirus (COVID-19) update: FDA continues user-fee related reviews through COVID-19. PR Newswire. 2020 Apr 16.